Wk3 - Haematology Flashcards
Site of haemopoiesis in foetus, infants and adults
Foetus:
0-2 months - yolk sac
2-7 months - liver, spleen
5-9 months - bone marrow
Infants: Bone marrow (all bones - not just axial skeleton)
Adults: Bone marrow (vertebrae, ribs, sternum, skull, sacrum, pelvis, ends of femurs)
Pluripotent stem cell divides to
Myeloid stem cell and lymphoid stem cell
Haemopoietc stem cell characteristics
Self renewal capacity
Unspecialised
Ability to differentiate (mature)
Quiescent (i.e. not undergoing cell cycle, in in G0) - only undergoes occasional cell division
Where are haemopoietic stem cells found?
Bone marrow
Peripheral blood after treatment with G-CSF (stem cells can be obtained out of bone marrow by G-CSF)
Umbilical cord blood
Haemopoietic stem cells can underrgo one of 3 things,,,
Self-renewal (identical copy)
Apoptosis
Differentiation
Haemopoietic stem cells can undergo one of 3 types of differentiation
1) Symmetrical division, contraction of stem cell numbers
2) Asymmetrical division, maintenance of stem cell numbers
3) Symmetrical division, expansion of stem cell numbers
Stroma = ?
The bone marrow microenvironment that supports the developing haemopoietic cell
Rich environment for growth and development of stem cells.
Stromal cells supported by an extracellular matrix.
BOne marrow microenvironemnt contains a number of different cells…
e.g. macrophages, fibroblasts, endothelial cells, fat cells, reticulum cells
These produce e.g. collagen, fibronectin, laminin, proteoglycans
What site is bone marrow aspirate taken from?
Iliac crest
Hereditary conditions impairing bone marrow function?
Thalassaemia, sickle cell anaemia, Fanconi anaemia, Schwachman-Diamond syndrome Hereditary leukaemia (very rare)
Acquired conditions impairing bone marrow function
Aplastic anaemia, leukaemia, myelodysplasia, myeloproliferative disorders, lymphoproliferative disorders, metastatic malignancy e.g. breast, infections e.g. TB/HIV, drugs and toxins, chemotherapy, haematinic deficiency
Principles of leukaemogenesis
HSC–> LSC –> Clonogenic leukemia cells –> non-clonogenic leukaemia blast cells
A multistep process
Neoplastic cell is a haemopoietic stem cell or early myeloid or lymphoid cell.
Dysregulation of cell growth and differentiation (associated with mutations)
Proliferation of the leukaemic clone with differentiation blocked at an early stage.
Haematological malignancies and pre-malignant conditions are termed ___ if they arise from a single ancestral cell
‘clonal’
Chronic myelogenous leukemia
Increase in WBCs (from myeloid lineage)
CML is acuased by BCr gene on chromosome 22 translocating to Abl gene on chromosome 9 –> this creates a new type of chromosome - Philadelphia chromosome.
This leads to increased pleuripotent stem cell production from bone marrow –> increased WBC
Chronic myelogenous leukemia
Increase in WBCs (from myeloid lineage)
CML is caused by BCr gene on chromosome 22 translocating to Abl gene on chromosome 9 –> this creates a new type of chromosome - Philadelphia chromosome.
This leads to increased pleuripotent stem cell production from bone marrow –> increased WBC
Myeloproliferative disprders =
clonal disorders of haemopoiesis leading to increased numbers of one or more mature blood progency
Classical MPDs (myeloproliferative disorders) are…
Polycythaemia rubrae vera (inc. RBCs)
Essential thrombocytosis (inc. platelets)
Myelofibrosis (inc. fibrous tissue)
Myeloproliferative disorders are variably associated with what mutation
JAK2V617F (point mutation) and calreticulin mutation
Myeloproliferative disorders have potential t transform into
AML
Clinical features of essential thrombocytosis
50% cases carry JAK2v617F, 50% carry calreticulin mutation.
Continuum with PRV Thrombotic complications Haemorrhagic complications Splenomegaly Transformation to PRV or myelofibrosis Leukaemic transmation in 3%
Treatment of essential thrombocytosis
Low risk (<40y with no high risk features e.g. diabetes) - aspirin or anti-platelet agent
Intermediate risk (40-60y with no high risk features) - aspirin +/- hydroxycarbamide)
High risk (>60y with thrombotic risk factors): 1st line = hydroxycarbamide + aspirin 2nd line = anagrelide + aspirin IFN alpha -usefu with pregnancy Busulphan (e.g. someone not independent) JAK2 inhibitors e.g. ruxolitinib
Describe JAK2 inhibitors
JAK2 mutations result in continuous activation of JAK receptor regardless of ligand binding
Ruxolitinib - inhibits JAK1 and 2, reduces splenomegaly, main side effect is thrombocytopenia, results in jak2 pos and neg patients
Describe myelodysplastic syndromes (MDS)
Characterised by dysplasia and ineffective haemopoiesis
May be secondary to previous chemotherapy or radiotherapy.
May have increased myeloblasts.
Often associated with acquired cytogenic abnormalities e.g. monosomy 5, monosomy 7, trisomy 8.
Majority characterised by progressive bone marrow failure
Some progress to AML
MDS clinical features
Predominantly affects the elderly
Majority present with fatigue due to anaemia
Fewer present with infections or bleeding or FBC
MDS management
Supportive caare - blood and platelet .transfusion.
Growth factors - Erythropoietin +/- granulocyte colony stimulating factor (G-CSF).
Immunosupression - anti-thymocyte globulin (ATG).
Low dose chemotherapy - e.g hydroxycarbamide, low dose cytarabine.
Demethylating agents - e.g. azacytidine, an epigenetic therapy.
Intensive chemotherapy - AML type chemotherapy.
Allogenic stem cell transplantation - only in selected patients
Features of fanconi anaemia
How is aplastic anaemia diagnosed?
Fanconi anaemia makes up 10-20 % of aplastic anaemia cases
Autosomal recessive inheritance Characteristics: Somatic abnormalitis e.g. skeletal deformities. Bone marrow failure Short telomeres Malignancy Chromosome instability
Features: microphthalmia GU malformations GI malformations Mental retardations Mental retardation Hearing loss CNA e.g. hydrocephalus
Currently 7 genetic sub-types FANCA-G
Aplastic anaemia diagnosed - definitively diagnosed through bone marrow biopsy –> most stem cells are gone and replaced by fat
Treatment of fanconi anaemia
Main cause of mortality is premature bone marrow failure
Gold standard therapy is allogenic stem cell transplant
Corticosteroids
Androgens (oxymethalone) - to increase blood counts
Lifetime surveillance for secondary tumours
Possibility of gene therapy in future where faulty FANC gene is replaced
Types of stem cell transplant
Autologous - uses patients own stem cells
Allogenic - stem cells come from a donor. - 5 types:
1. Syndeneic - identical twins
2. Allogenic sibling - HLA identical
3. Haplotype identical - half matched family member. Usually a parent or half matched sibling
4. Volunteer unrelated (VU) - akak matched unrelated (MUD)
5. Umbilical cord blood
Main indications for autologous stem cell transplant
relapsed Hodgkin’s disease, non Hodgkins lymphoma and myeloma, chronic leukaemia
Preparation for autologous transplant
Patients receive growth factor (G-CSF) +/- chemotherapy to make the stem cells leave the bone marrow so they can be collected from the blood.
Mozobili has been used to collect stem cells in patients that have failed to mobilise
Features of umbilical cord blood transplant
Blood stem cells collected from umbilical cord and placenta.
Cells are tissue typed and frozen in liquid nitrogen in cord blood banks for future use
Advantages and disadvantages of umbilical cord transplant
Advan: more rapidly available in VUD, less rigorous matching to patient type of patient as immune system naive
Disadvan: if relapse, cannot go back for DLI
Describe graft versus host disease (GvHD)
Can happen in patients who have receieved an allogenic transplant. The new donor’s immune system recognises the host’s body as ‘foreign’ and start to attack it.
Most commonly manifests as a skin rash, jaundice or diarrhoea
What are the 2 types of GvHD
Acute GvHD - occurs within the first 100 days of the transplant
Chronic GvHD - occurs after first 100 days of transplant
GvHD is usually treated with …
immunosuppressive agents
GvL (graft vs leukaemia effect)
the same cells which cause GvHD also attack remaining leukaemic cells. GvL is very effective, especially in patients where a good remission has been difficult to maintain. Can also work in other blood cancers such as lymphoma and myeloma.
Minimising GvHD carries an increased risk of relapse.
In an autologous transplant there is no GvHD and therefore no GvL resulting in a greater risk of a relapse.
The challenge is to minimise GvHD and maximise GvL.
Anaemia = ? Polycythaemia = ?
Know about aplastic anaemia
Too little blood
Too much blood
Aplastic anameia - This is damage to haemopoietic stem cells, resulting in deficiency of all 3 blood cell types –> Pancytopenia (thrombocytopenia, leukopenia, anaemia)
1 molecules of Hb contains
Describe the requirements of normal red cell production
4 globin chains (2 alpha, 2 beta)
4 haem groups
Erythropoietin - drive for eryhtropoiesis Genes for the process Iron Vitamin B12 Folate and other minerals Functioning bone marrows No inc loss or destruction of RBCs
Transferrin
Involved in iron transport is a glycoprotein Synthesised in hepatocytes Dec. iron = inc. Tf Inc. iron = dec. Tf 2 iton binding sites. 30% saturated with Fe Tf delivers iron to all tissues, erythroblasts, hepatocytes, muscle etc.
RES storage and recycling
Effete red blood cells are removed by the macrophages of the reticuloendothelial system (RES) (RBC lifespan 120d)
The RES stores 500mg of iron
RES iron is stored in ferritin/haemosiderin
RES releases iron to Tf in plasma
Tf-iron taken up via Tf receptors on erythroblasts, hepatocytes etc.
Hepcidin
Is the ‘low iron’ hormone - it reduces levels of iron in plasma. Hereditary haemochromotosis dt loss of Hepcidin.
Hepcidin binds ferroportin and degrades it - reducing iron absoprtion (enterocyte) and decreasing iron release from the RES.
Hepcidin is synthesised in the liver (requires expression of HFE)
4 causes of hypochromic microcytic RBCs
IDA (not enough haem)
Thalassaemia (not enough globin)
ACD
Sideroblastic anaemia (particularly congenital SA)
iron and transferrin saturation levels
Normal - 30%
IDA - <15%
Low serum ferritin always indicates …
low RES iron stores
How can IDA occur with normal serum ferritin levels
In presence of tissue inflamamtion (RA & IBD)
Signs of IDA
Diagnosis of IDA
Koilonychia
Atrophic Glossitis
Angular stromatitis
Oesophageal web (plumer vinson syndrome)
Hypochromic microcytic RBCs
<15% saturation transferrin
Low serum ferritin –> always indicates low RES iron stores
Causes of IDA
Dietary - premature neonates, adolescent females
Malabsorption
Blood loss
Levels of menorrhagia
> 80mls blood/period
Golden rule of IDA
IDA in males and post-menopausal females is due to F=GI blood loss until proven otherwise
Young women; menstrual blood loss +/- pregnancy
Iron replacement in IDA
Ferrous sulphate
Ferrous Gluconate
IV iron (when- intolerant to oral iron, complicance, renal anaemia & Epo replacement
Describe Anaemia of Chronic Disease (ACD)
Failure of iron utilisation
iron trapped in RES
Causes - infection, inflammation, neoplasia
Pathophysiology ACD = Iron is trapped in REs within macrophages, causing a reduced Epo response. This results in depressed marrow activity –> cytokine marrow depression
Anaemia of CRF = ACD + dec. Epo
Lab values in ACD
MCV/MCH N/dec. - normochromic normocytic or hypochromic microcytic RBCs ESR - inc. (RBC Rouleaux) Ferritin - N/inc. Iron - dec. TIBC - dec.
Causes of ACD
RE Iron blockade; iron trapped in macrophages; raised levels of Hepcidin
Reduced Epo response
DEpressed marrow activity; cytokine marrow depression
Treatment of ACD
Treat underlying disorder
B12/folate is essential for…
DNA synthesis and nuclear maturation.
Required for all dividing cells, deficiency noted first in red cells
DEficiency in B12/folate
results in megaloblastic anaemia intitially, but will effect other organs
B12 (Cobalamin) is necessary for 2 processes -
Methylation of homocysteine to methionine
Methylmalonyl-CoA isomerisation
Dietary sources of B12
Meat (esp. iver and kidney), small amount in dairy products
Normal western diet 5-30ug/day
Daily requirement - 1ug/day
Describe B12 absorption
B12 ingested (in form of animal protein).
Gastric pariteall cells in fundus/body produce Intrinsic factor.
B12 released by enzymes/acid in sotmach and duodenum.
Intrinsic Factor binds to B12 in duodenum/jejunum.
IF-B12 complex binds to cubulin (specific receptor in ileum) - is absorbed in ileum.
B12 absorbed and binds to transcobalamin in the blood.
B12 stored for …
3-4 years
Folate - dietary stores, absorption, stores
Green veg (destroyed by cooking)
Absorption - mostly small bowel. No carrier molecule required.
Stored - few days only - quickly used up if increased demand (ie increased cell turnover)
Clinical B12 deficiency - blood abnormalities and neurological manifestations
Megaloblastic anaemia (leucopenia, thrombocytopenia)
Bilateral peripheral neuropathy or demyelination of the posterior and pyramidal tracts of spinal cord. (likely related to problem with homocysteine -> methionine
Clinical folate deficiency - blood abnormalities and growing fetus
Megaloblastic anaemia (leucopenia and thrombocytopenia)
1st 12 weeks - deficiency can cause neural tube defects
Signs and symptoms of B12/folate deficiency
Symptoms of anaemia/cytopenia:
Tired - macrocytic/megaloblastic anaemia (common); easy bruising - thrombocytopenia (rare)
Mild jaundice - haemolysis
Neurological problems - nerve disturbance as a result of B12 def - subacute combined degeneration of cord
Causes of folate deficiency
Dietary
Extensive small bowel disease - coeliac, sever Crohns
Increased cell turnover - haemolysis, severe skin disorders, pregnancy
Components of HbA and HbF
Develop a logical approach to the investigation of a patient with anaemia
HbA - 2alpha, 2 beta
HbF - 2alpha, 2gamma
Is the information new? - helps determine congenital or acquired
Any clues in the history? - blood loss, diet, chronic disease, family history, medication etc.
Examination findings - angular stromatitis, splenomegaly, lymphadenopathy, abdominal passes
Blood film
Coombs test - this is used to test for autoimmune haemolytic anaemia:
Direct Coombs test - This is used to detect antibody on RBC surface. Blood sample is taken and RBCs washed to removed own plasma, which they are then incubated with anti-human globulin. If this produces agglutination of RBCs, positive test –> shows AIHA or HDN
Indirect Coombs test - This is sued to detect RBS antibodies within the plasma during prenatal testing of pregnant women, and in testing blood prior to blood transfusion. Serum extracted from blood sample and incubated with RBCs of a known antigenicity. If agglutinaiton occurs, positive test
Provide examples of diseases causing anaemia
Thalassaemias =
Thalassaemias, Haemoglobin chain variants, Haemolytic anaemia (congenital and acquired (warm and cold type))
relative lack of normal globin chains due to absent genes
Clinical significance of alpha thalassaemia
Missing one gene - mild microcytosis
Missing 2 genes - micorcytosis, increased red cell count and sometimes very mild (asymptomatic) anaemia
Missing 3 genes - significant anaemia and bizarre shaped small red cells - Haemoglobin H (HbH) disease
Missing 4 genes - incompatible with life (need alpha chains for fetal haemoglobin) - alpha thalassaemia major
Featurs of Hbh disease
Missing 3 alpha genes
Lack og alpha chains -> excess beta chains
Beta chains end up joining together (HbH)
Blood transfusion require during periods of stress
Hb variable 65-75g/l
Features of beta thalassaemia major
missing both beta globin genes.
Autosomal recessive
Unable to make adult haemoglobin (HbA)
Significant dyserythropoiesis (poorly functioning RBCs)
Hypochromic, will have splenomegaly and CF
Maxillary prominence
Thicker skull
Presentation and treatment/management of beta thalassaemia major
Don’t feed well, falling off centile, smaller stature
Transfusion dependent from early life (first couple of years)
Ion overload has major effect on life expectancy
pathogenesis of sickle cell disease
Chromosome 11:
Single amino acid substitution on B globin gene at position 6
Glutamine>Valine = Hb S
(Glutamine>Lysine = HbC)
HbS = 2 alpha + 2 beta (sickle) = (a2bs2)
Describe how sickle cell anaemia is described as a multisystem disease
Brain - stroke
Lungs - acute chest syndrome, pulmonary hypertension
Bones - Dactilytis, osteonecrosis
Spleen - hyposlenic
Kidneys - loss of ocncentration, infartion
Urogenital - priapism - chronic, acute
Eyes - vascular retinopathy\Placenta - IUGR/fetal loss
Treatment of sickle cell anaemia
Prevent crissi - hydration, analgesia, early intervention, prophylactic vaccination and antibiotics, folic acid
Prompt manageemnt of crises - oxygen, fluids, analgesia, antibioticis, transfusion/red cell exchange
Bone marrow transplantation